Physician profile
Timothy D Law
NPI 1124095310
$20,998.06
in general payments reported to CMS, 2019-2025
15 companies · $2,756 in 2025
The $2,756 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.46 · 2021: $8,917 · 2022: $1,865 · 2023: $2,862 · 2024: $4,586 · 2025: $2,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,707 · Travel and Lodging: $933 · Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,707.00 |
| Travel and Lodging | $932.74 |
| Food and Beverage | $564.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $6,934.29 | 2023-2025 | Lynozyfic |
| Genzyme Corporation | $5,202.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $4,840.00 | 2021-2023 | |
| Celgene Corporation | $1,925.00 | 2021 | |
| Invivyd INC | $1,600.00 | 2025 | Pemgarda |
| Abbvie INC. | $180.16 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $131.90 | 2021-2024 | |
| Lilly USA, LLC | $44.79 | 2023 | Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.37 | 2021-2022 | |
| Boston Scientific Corporation | $22.33 | 2023 | |
| Dexcom, INC. | $20.18 | 2023 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $19.37 | 2022 | |
| Smith+Nephew, INC. | $19.27 | 2023 | Stravix |
| Abbott Laboratories | $18.94 | 2025 | Freestyle Libre 3 |
| Mayne Pharma Commercial LLC | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.